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The mechanisms by which sphingosine
kinase-1 (SK-1)/sphingosine 1-phosphate
(S1P) activation contributes to imatinib
resistance in chronic myeloid leukemia
(CML) are unknown. We show herein that
increased SK-1/S1P enhances Bcr-Abl1
protein stability, through inhibition of its
proteasomal degradation in imatinib-
resistant K562/IMA-3 and LAMA-4/IMA hu-
man CML cells. In fact, Bcr-Abl1 stability
was enhanced by ectopic SK-1 expres-
sion. Conversely, siRNA-mediated SK-1
knockdown in K562/IMA-3 cells, or its
genetic loss in SK-1/ MEFs, signifi-
cantly reduced Bcr-Abl1 stability. Regula-
tion of Bcr-Abl1 by SK-1/S1P was depen-
dent on S1P receptor 2 (S1P2) signaling,
which prevented Bcr-Abl1 dephosphory-
lation, and degradation via inhibition of
PP2A. Molecular or pharmacologic inter-
ference with SK-1/S1P2 restored PP2A-
dependent Bcr-Abl1 dephosphorylation,
and enhanced imatinib- or nilotinib-
induced growth inhibition in primary
CD34 mononuclear cells obtained from
chronic phase and blast crisis CML pa-
tients, K562/IMA-3 or LAMA4/IMA cells,
and 32Dcl3 murine progenitor cells, ex-
pressing the wild-type or mutant (Y253H
or T315I) Bcr-Abl1 in situ. Accordingly,
impaired SK-1/S1P2 signaling enhanced
the growth-inhibitory effects of nilotinib
against 32D/T315I-Bcr-Abl1–derived mouse
allografts. Since SK-1/S1P/S1P2 signal-
ing regulates Bcr-Abl1 stability via modu-
lation of PP2A, inhibition of SK-1/S1P2
axis represents a novel approach to tar-
get wild-type- or mutant-Bcr–Abl1 thereby
overcoming drug resistance. (Blood. 2011;
117(22):5941-5952)
Introduction
CML is a clonal disorder of pluripotent hematopoietic stem cells
characterized by the Philadelphia (Ph) chromosome, which results
from the reciprocal translocation between the long arms of
chromosomes 9 and 22.1-4 This hybrid B-cell receptor (BCR)–ABL1
gene encodes for a fusion protein Bcr-Abl1 with a constitutive
tyrosine kinase activity.3,4
Despite high rates of clinical responses in early chronic phase
CML (CML-CP) to the Bcr-Abl1 kinase inhibitor imatinib,5-8
development of resistance is a major problem in late CML-CP and
in the treatment of blast crisis CML (CML-BC).9-12 Although
Bcr-Abl1–independent mechanisms also exist,13-15 resistance in
CML-CP is usually associated with the expression of mutant
Bcr-Abl1 proteins, including T315I and Y253F/H mutations against
which the second generation ABL tyrosine kinase inhibitors (TKI)
such as nilotinib and/or dasatinib show limited effect.15-17 Nonethe-
less, BCR-ABL1 mutations may not account for all cases of drug
resistance in CML (CP and BC); indeed, alternative Bcr-Abl1–
dependent mechanisms including alterations of sphingolipid metab-
olism and signaling,18 might account for TKI resistance.
Sphingolipids, ceramide and sphingosine 1-phosphate (S1P)
included, are a family of membrane lipids with important roles
in the regulation of the fluidity and subdomain structure of
membranes.19-21 Ceramide can be hydrolyzed by ceramidases to
release sphingosine, which is phosphorylated by sphingosine
kinases-1 or -2 (SK-1 or SK-2) to generate S1P.20 Ceramide
plays proapoptotic roles21 whereas S1P mediates proliferation
and/or resistance to apoptosis22,23 generally via G-protein–
coupled S1P1-5 receptor signaling.24 However, receptor-
independent intracellular functions of S1P were also reported.25
Recently, alteration of the balance between the proapoptotic
ceramide and antiapoptotic S1P via up-regulation of SK-1 was
shown to mediate imatinib resistance in K562 CML-BC patient-
derived cells by an unknown mechanism.18
Here, we report the identification of a novel mechanism by
which SK-1/S1P mediates imatinib resistance by regulation of the
PP2A-dependent and SHP-1–mediated Bcr-Abl1 dephosphoryla-
tion and stability selectively via receptor 2 (S1P2) signaling in
CML (CP and BC). In addition, our data suggest that targeting the
SK-1/S1P2 signaling axis provides a novel strategy to modulate
wild-type (wt) or mutant (T315I or Y253H) Bcr-Abl1 stability by
restoring PP2A function, and attenuate drug resistance both in cell
culture and in mice bearing 32D/T315I-Bcr-Abl1 allografts.
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Methods
Cell lines and growth conditions
Human CML cell lines K562, LAMA4, and their imatinib-resistant
derivatives K562/IMA-0.1, -1, -3, or LAMA4/IMA, were maintained as
described.18 The Bcr-Abl–expressing 32Dcl3 cells, 32D-p210Bcr-Abl (wt),
32D-p210Bcr-Abl (Y253H) and (T315I) were maintained in RPMI containing
15% FBS, 2mM L-glutamine, and penicillin and streptomycin (P/S;
100 ng/mL each). MEFs (wt and SK-1/) were maintained in DMEM with
10% FBS and P/S. Human CD34 primary cells from CML patients and
normal donor were obtained under a protocol approved by the institutional
review board and IACUC at the Medical University of South Carolina or
The Ohio State University and were grown as described.26
Quantitative real-time PCR and Western blotting
Quantitative real-time PCR (Q-RT-PCR) was performed using TaqMan
gene expression kit (Applied Biosystems) with ABI 7300 Q-PCR system.
All primers and probes were obtained from ABI. The mRNA of GAPDH
and rRNA were used as internal controls.18
Bcr-Abl1, P-Bcr–Abl1-Y245 or -Y177, SK1, PP2A, PP2A-pY307,
SHP1, SHP1-pS591, V5, HA, GAPDH and -actin protein was measured
by Western blotting using mouse monoclonal anti–c-Abl antibody-3
(Calbiochem), rabbit polyclonal anti–Bcr-Abl1-pY245 or -pY177 (Cell
Signaling), rabbit polyclonal anti-SK1,27 mouse monoclonal anti-PP2A
(Millipore), rabbit polyclonal anti–P-PP2A-Y307 (Epitomics), mouse mono-
clonal anti-SHP1 (Santa Cruz), rabbit polyclonal anti–P-SHP1-S591 (ECM
Biosciences), mouse monoclonal V5 (Invitrogen), mouse monoclonal
anti-HA (Cell Signaling), mouse monoclonal anti-GAPDH (Millipore),
rabbit polyclonal anti–-actin (Sigma-Aldrich) and peroxidase-conjugated
secondary anti–rabbit or anti–mouse antibodies (Jackson ImmunoResearch
Laboratories).18 The quantification of blots were performed using ImageJ
Version 1.44.
Measurement of SK activity, and S1P generation using LC/MS
The endogenous activity of SK for S1P generation was measured using
C17-Sph (5M) labeling in K562 and K562/IMA-3 cells followed by the
detection of C17-S1P in cell extracts at various time points using LC/MS/MS
as described.28
Plasmids and siRNAs
Overexpression of the V5-tagged SK-1, and HA-tagged PP2Ac was
obtained by Amaxa nucleofection. I2PP2A (SET)-GFP was expressed in
resistant K562 cells as described.29 The siRNAs were obtained from
Dharmacon, and their specificity for target genes was confirmed by Q-PCR
and/or Western blotting.29 Cells were transfected by siRNA (100nM for
48 hours) using Amaxa nucleofection. The siRNAs for SK-1, SK-2 and
S1P1-4 receptors were obtained from Dharmacon (smart-pool siRNAs).
Determining the half-life of Bcr-Abl1 protein
The half-life of Bcr-Abl1 was determined using cycloheximide (CHX,
80 g/mL) as described.30 Bcr-Abl1 stability was further examined by
pulse-chase experiments, in which sensitive and resistant cells were pulsed
with [35S]-methionine/cysteine, 150 Ci/mL for 18 hours, or [32P]-
orthophosphate, 0.5 mCi/mL for 4 hours, (American Radiolabeled Chemi-
cals) in amino acid– or phosphate-depleted media, respectively. Labeled
proteins were then chased in intact media for various time points. Total and
P-Bcr-Abl1 proteins were immunoprecipitated, resolved on SDS-PAGE,
and visualized by autoradiography as described.30
Detection of cell growth and apoptosis
The growth of cells was measured using trypan blue exclusion and
3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyltetrazolium bromide; 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assays as de-
scribed.18 Activation of caspases 3 and 9 in cell extracts was determined
using their fluorescently labeled specific target peptides, as described by the
manufacturer (Fluorometric Caspase Assay Kit; R&D Systems).29
Detection of the ubiquitination of Bcr-Abl1
The ubiquitination of Bcr-Abl1 was detected in the presence/absence of a
proteasome inhibitor (lactacystin; AG Scientific), or expression of the
exogenous ubiquitin, using an HA-ubiquitin vector, by immunoprecipita-
tion followed by Western blotting using anti–Bcr-Abl1 or anti-HA antibod-
ies, as described.31 Protein-antibody complexes were pulled down using
protein A/G agarose beads for 60 minutes at 4°C, which were then washed
and resuspended in 10 L of 1 PBS and 10 L of 2 loading buffer. After
incubation at 95°C for 5 minutes, proteins were separated by SDS-PAGE
and examined by Western blot analysis.
Measurement of PP2A activity
Phosphatase assays in cell extracts were carried out using the PP2A
phosphatase assay kit (Upstate). Briefly, protein lysates (50 g) in 100 L
of 20mM N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid (pH 7.0)/
100mM NaCl, 5g of PP2Ac antibody (Upstate), and 25 L of Protein
A-agarose were added to 400 L of 50mM tris(hydroxymethyl)aminometh-
ane (pH 7.0)/100mM CaCl2, and immunoprecipitations were carried out at
4°C for 2 hours. Immunoprecipitates were washed, and phosphatase
activity was measured by malachite green reaction measuring free phos-
phate released from phosphothreonine peptide (K-R-pT-I-R-R), as de-
scribed by the manufacturer.
Cell staining and sorting
Flow cytometry staining for analysis of hematologic cell types were
performed using antibodies and lineage markers using flow cytometry as
described.32
Analysis of 32D/wt- and 32D/T315I-Bcr-Abl1 allograft growth
and TKI sensitivity in response to SK-1/S1P2 interference in
mice
Severe combined immunodeficiency mice were (n  4/group) injected
subcutaneously with either 32D/wt Bcr-Abl cells, or 32D/T315I-Bcr-Abl
cells (4  106 cells in each flank), and tumor growth was monitored weekly
by calipers.29 Mice were treated with nilotinib at 10 mg/kg, in the
absence/presence of SKI-II or JTE-013 (Cayman Chemicals; 15 or 0.5
mg/kg, respectively) at days 1, 8, 15, and tumor growth was measured at
days 1, 6, 11, 14, and 18 after treatments. Independent experiments were
performed at least twice in duplicates or triplicates. Statistical significance
was examined using Student t test analysis, and P  .05 was considered
significant.29
Results
SK-1/S1P mediates increased protein stability of Bcr-Abl1
Our previous data indicated that increased generation of S1P by
SK-1 mediates drug resistance via up-regulation of Bcr-Abl1
protein but not mRNA levels in K562/IMA-1 cells.18 To define the
role of SK-1/S1P signaling in the regulation of Bcr-Abl1, we
compared total (Bcr-Abl1) and Y245 or Y17733 phosphorylated
(P-Bcr-Abl1) proteins with regard to SK-1 expression and activity
in sensitive K562 versus resistant K562/IMA-3 cells, which were
derived by chronic exposure to 3M imatinib. Bcr-Abl1 and
P-Bcr-Abl1 levels were up-regulated approximately 2.0- and
2.5-fold, respectively, in K562/IMA-3 compared with K562 cells
(Figure 1A). The mRNA, protein and the activity of SK-1 was also
increased approximately 2.8-, 3.0-, and 3.5-fold, respectively, in
K562/IMA-3 cells (supplemental Figure 1A-C, available on Blood
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Web site; see the Supplemental Materials link at the top of the
online article). Because B-cell receptor-ABL1 mRNA did not
significantly change in K562/IMA cells,18 we examined the protein
stability of Bcr-Abl1 using cycloheximide (CHX) at 80 g/mL.
The half-life of Bcr-Abl1 was around 24 hours in K562 cells, and it
was	 36 hours in K562/IMA-3 cells (Figure 1B). These data were
also consistent when pulse-chase labeling with [35S]-methionine/
cysteine was performed to examine the half-life of Bcr-Abl1 in
these cells without CHX (data not shown). Moreover, the stability
of P-Bcr-Abl1 was also measured using [32P]-orthophosphate
labeling and immunoprecipitation, which revealed that the half-life
of P-Bcr-Abl1 (at Y117) was around 16 hours in K562 versus
	 24 hours in K562/IMA-3 cells (Figure 1C). Thus, stability of
Bcr-Abl1 and activated P-Bcr-Abl1 is higher in imatinib-resistant
than -sensitive K562 cells.
To assess whether SK-1/S1P plays a role in the stabilization of
Bcr-Abl1, we investigated the effects of SK-1 overexpression on
the half-life of Bcr-Abl1 in K562 cells. Ectopic SK-1-V5 expres-
sion (supplemental Figure 2A), strongly increased Bcr-Abl1 half-
life from around 22 to 32 hours (Figure 1D). Accordingly,
siRNA-mediated SK-1 knockdown (approximately 60% reduction
by Q-PCR, supplemental Figure 2B), impaired SK activity of 40%
(supplemental Figure 2C), thereby reducing Bcr-Abl1 levels of
around 58% in K562/IMA-3 cells compared with same cells
exposed to scrambled (Scr) siRNAs (Figure 1E). Moreover, the
role of SK-1/S1P in the regulation of Bcr-Abl1 stability was also
examined in MEFs isolated from wt or SK-1/ knockout mice,
transduced with a B-cell receptor-ABL1-GFP vector, in the absence/
presence of CHX for 18 and 30 hours. As expected Bcr-Abl1-GFP
was stable in wt-MEFs, whereas its expression in SK-1/ MEFs
was 40% and 65% decreased at 18 and 30 hours, respectively
(Figure 1F), further strengthening the notion that SK-1 positively
modulates Bcr-Abl1 stability. Furthermore, these data suggest that
SK-1 decreases TKI sensitivity by increasing Bcr-Abl1 stability/
expression, consistent with the reported ability of SK-1 to regulate
imatinib-induced apoptosis in TKI-sensitive and -resistant
K562 cells.18
SK-1/S1P-dependent Bcr-Abl1 stability is regulated selectively
via S1P2 signaling
Levels of S1P2 and S1P4 mRNAs were found increased in
K562/IMA-1 compared with K562 cells previously,18 however
their specific involvement in drug resistance was not assessed. Note
that the expression of S1P5 was undetectable in these cells.18
Therefore, roles of S1P1-4 signaling in the regulation of Bcr-Abl1
expression by SK-1/S1P were determined using siRNAs in K562/
IMA-3 cells. The specificity of S1P1-4 siRNAs against their target
genes (around 50%-80% knockdown) was confirmed using Q-PCR
(supplemental Figure 3). Interestingly, knockdown of only S1P2,
but not S1P1, 3 or 4, decreased Bcr-Abl1 approximately 50%
compared with controls in K562/IMA-3 cells (Figure 2A). Down-
regulation of S1P2 did not affect BCR-ABL1 mRNA levels (data
not shown). Moreover, S1P2 knockdown (around 60% as shown by
Figure 1. Regulation of the stability and expression of Bcr-Abl1 by SK-1/S1P signaling. (A) Total and P-Bcr-Abl1 (Y245) in K562/IMA-3 compared with K562 cells (lanes
2 and 1, respectively) were measured using Western blotting. -actin was used as a loading control. (B) The protein stability of Bcr-Abl1 in K562 and K562/IMA-3 cells was
measured by Western blotting at various time points (0-36 hours) using CHX. Long-lived protein GAPDH was used as a control. Relative expression levels of Bcr-Abl1
(normalized to GAPDH levels) at 0-36 hours after CHX treatment in K562 versus K562/IMA-3 cells are shown. (C) The stability of P-Bcr-Abl1 in K562 and K562/IMA-3 cells
were also examined by pulse-chase experiments using [32P]-orthophosphate labeling without CHX using immunoprecipitation by anti–P-Bcr-Abl1 (Y177) antibody. (D) The
protein stability of Bcr-Abl1 in response to overexpression of SK-1 with the V5 tag in K562 parental cells was determined at various time points (0-36 hours) compared with
vector-transfected controls using Western blotting. GAPDH was used as a loading control (left panel). (E) The expression of SK-1 was down-regulated using siRNA, and its
effect on the stability of Bcr-Abl1 was determined using CHX treatment at 12 hours compared with Scr-siRNA treated controls. (F) Effects of genetic loss of SK-1 on Bcr-Abl1
stability were examined in wt and SK-1/ MEFs stably transfected with the human wt-Bcr-Abl1-GFP (p210) in the presence of CHX at 0, 18, 30 hours. The stability of
P-Bcr-Abl1-GFP in wt versus SK-1/ MEFs was measured using [32P]-orthophosphate labeling and immunoprecipitation (using the antibody that recognizes P-Bcr-Abl1 at Y177) as
described in “Determining the half-life of Bcr-Abl1 protein.” These experiments were performed in duplicates, and error bars represent SD. *P  .05 was considered significant.
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Q-PCR, supplemental Figure 3) in TKI resistant cells reduced
Bcr-Abl1 half-life (around 24 hours; Figure 2B third panel
compared with first panel lanes 1-4, respectively), making it similar
to that of TKI sensitive cells.
Then, we examined the effects of S1P1, or S1P2 siRNAs in the
absence/presence of exogenous S1P (1M) on Bcr-Abl1 expres-
sion in K562/IMA-3 cells. Down-regulation of S1P2, but not S1P1,
reduced P-Bcr-Abl1 (approximately 50%) and total Bcr-Abl1 (data
not shown) compared with scrambled siRNA-treated controls
(Figure 2C). Addition of S1P almost completely prevented the
down-regulation of P-Bcr-Abl1 in response to S1P2 siRNA
compared with controls (Figure 2C). Thus, these data suggest that
knockdown of S1P2, but not S1P1, mediates the down-regulation
of Bcr-Abl1, which is prevented by exogenous S1P.
In reciprocal experiments, lentiviral-mediated stable S1P2-GFP
expression, approximately 2-fold (measured by Q-PCR, Figure
2D), in sensitive K562 cells using a lenti-viral transduction,
decreased imatinib-induced (0.3, 0.5, and 1.0M) growth suppres-
sion of 40% only in the presence of exogenous S1P (0.5M)
compared with vector-transfected control cells (Figure 2E). Over-
expression of S1P2 alone (without S1P) did not have any signifi-
cant effect on imatinib-induced cell death in K562 cells (Figures
2E). These data suggest that over-expression of S1P2 mediates
imatinib resistance only in the presence of an additional S1P in
sensitive K562 cells, indicating the involvement of increased S1P
(exogenously supplied, or endogenously generated by SK-1)
upstream of S1P2 signaling in Bcr-Abl1 expression and imatinib
resistance.
Accordingly, inhibition of S1P2 by JTE-01334 at 10 M
(24 hours) decreased P-Bcr-Abl1 (approximately 50%) in sensitive
K562 cells, and addition of S1P (0.5M) increased P-Bcr-Abl1
approximately 30% compared with controls (Figure 2F). Impor-
tantly, JTE-013 treatment prevented up-regulation of P-Bcr-Abl1 in
response to S1P (Figure 2F). Note that inhibition of S1P1 or S1P1/3
by VPC23019, or W146, respectively, did not significantly change
P-Bcr-Abl1 in the presence of S1P (data not shown). Thus, these
data support that inhibition of S1P2, but not S1P1 or S1P3,
prevents S1P-mediated P-Bcr-Abl1 stability.
Then, the expression levels of SK-1 and S1P2 were examined in
LAMA-4 and their independently developed drug-resistant variant
Figure 2. Involvement of S1P2 signaling in SK-1/S1P-induced stability of Bcr-Abl1 in drug resistant compared with sensitive K562 cells. (A) Effects of the knockdown
of S1P1, S1P2, S1P3 and S1P4 using siRNAs on Bcr-Abl1 protein in K562/IMA-3 cells were examined using Western blotting compared with nontargeting scrambled (Scr)
controls. Actin was used as a loading control. (B) Effects of knockdown of S1P2 using siRNA on the stability of Bcr-Abl1 protein compared with controls (Scr siRNA transfected
cells) in the K562/IMA-3 drug resistant cells was measured at 0, 6, 12, and 24 hours after CHX treatments using Western blotting (first and third panels lanes 1-4, respectively).
GAPDH was used as a loading control (second and fourth panels). Relative expression levels of Bcr-Abl1 (normalized to GAPDH levels) at 0-24 hours post-CHX treatment in
cells transfected with Scr or S1P2 siRNAs are shown below each lane. (C) Effects of knockdown of S1P1, or S1P2 using siRNAs in the absence/presence of exogenous
BSA-conjugated S1P (1.0M, added every 3 hours for 24 hours) on P-Bcr-Abl1 were assessed in K562/IMA-3 cells using Western blotting. Actin was used as a loading control.
(D-E) Effects of overexpression of human S1P2-GFP using a lentiviral expression vector, as confirmed by Q-PCR (D) on imatinib-induced growth inhibition in sensitive
K562 cells at 0.3, 0.5, and 1.0M for 48 hours in the absence/presence of exogenous S1P (1M) were examined using trypan blue exclusion (E). Vector-transduced cells were
used as controls. (F) Regulation of P-Bcr-Abl1 (Y245) by S1P/S1P2 signaling was determined after treatment of K562 cells with 0.5M BSA-conjugated S1P for 24 hours in the
absence/presence of JTE-013 compared with untreated controls or JTE-013–treated cells using Western blotting. Actin was used as a loading control. These experiments were
performed in duplicates, and error bars represent SD. *P  .05 was considered significant.
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LAMA-4/IMA cells. SK-1 and S1P2 mRNAs were up-regulated
approximately 4- and 2-fold, respectively, in LAMA-4/IMA com-
pared with parental cells (Figure 3A). LAMA-4/IMA cells over-
expressed both Bcr-Abl1 and P-Bcr-Abl1 approximately 2.5 and
10-fold, respectively, compared with controls (Figure 3B lanes
2 and 1, respectively). Importantly, siRNA-mediated down-
regulation of SK-1 and/or S1P2, but not S1P1, which decreased
expression of their mRNAs of 60%-70% compared with scrambled
siRNA-treated controls (data not shown), significantly enhanced
(40%-50% increase) imatinib-induced growth inhibition at 0.5 and
1.0 M (Figure 3C). Knockdown of SK-1 and/or S1P2 also
decreased Bcr-Abl1 and P-Bcr-Abl1 expression by approximately
23%-30% or 50%-68%, respectively, compared with controls
(Figures 3D). Thus, these data indicate that SK-1/S1P/S1P2-
mediated regulation of Bcr-Abl1 stability, phosphorylation/
activation, and drug resistance is also conserved in human LAMA-
4/IMA cells.
SK-1/S1P signaling regulates Bcr-Abl1 stability via inhibition
of PP2A
The ubiquitination/degradation of Bcr-Abl1 protein is controlled
via its dephosphorylation by SHP1, a tyrosine protein phosphatase,
whose activation is regulated by PP2A.35 Therefore, we examined
the involvement of PP2A and SHP1 in the regulation of Bcr-Abl1
stability using 10nM okadaic acid (OA) or 10M sodium stiboglu-
conate (SS), inhibitors of PP2A or SHP1, respectively. In K562/
IMA-3 cells, inhibition of PP2A by OA increased Bcr-Abl1 protein
approximately 3-fold compared with untreated controls, however,
SS alone did not increase basal levels of Bcr-Abl1 (Figure 4A). As
expected, siRNA-mediated SK-1 knockdown decreased Bcr-Abl1
expression of 40% (Figure 4A), and suppression of PP2A or SHP-1
activity by OA or SS, respectively, rescued Bcr-Abl1 expression in
K562-IMA3 cells in response to SK-1 siRNAs (Figure 4A). These
results highlight the importance of the PP2A/SHP1/SK-1 interplay
in the regulation of Bcr-Abl1 expression/stability. Importantly,
siRNA-mediated 80% down-regulation of SK-2 did not alter
Bcr-Abl1 expression (supplemental Figure 4 left and right panels,
respectively). Thus, SK-1–, but not SK-2–generated S1P controls
Bcr-Abl1 protein stability through modulation of PP2A activity.
Indeed, SK-1 down-regulation by siRNAs rescued PP2A activity in
K562/IMA-3 cells, and decreased Bcr-Abl1 and P-Bcr-Abl1 levels
(Figure 4B and C, respectively). It was reported previously that
I2PP2A (SET) suppressed PP2A (approximately 50% compared
with controls) activity in vitro.29 Consistent with these data, ectopic
I2PP2A (SET) expression resulted in accumulation of the tyrosine
307 phosphorylated form of PP2Ac (Figure 4C fourth panel lanes
3-4 and 1-2), which, as reported,36 is indicative of PP2A inactiva-
tion. Importantly, while SK-1 siRNA mediated Bcr-Abl1 down-
regulation (both total and phosphorylated forms of 25%-32%,
respectively), I2PP2A (SET)-mediated inhibition of PP2A almost
completely prevented P-Bcr-Abl1 down-regulation in response to
SK-1 siRNA (Figure 4C first and second panels lanes 4-3 and 2-1,
respectively). Moreover, while knockdown of SK-1 reduced the
viability of LAMA-4/IMA resistant cells (approximately 50%),
I2PP2A blunted the growth inhibitory effects of SK-1 siRNA
(Figure 4D).
Figure 3. Roles of SK-1/S1P2 signaling in the regulation of Bcr-Abl1 expression and drug resistance in human LAMA-4 CML cells. (A) The mRNA levels of S1P2 and
SK-1 were measured (and normalized to the levels of rRNA) using Q-PCR in parental LAMA-4 and drug-resistant LAMA-4/IMA cells. (B) Bcr-Abl1 (total) and P-Bcr-Abl1 (Y245)
were examined in LAMA-4 and LAMA-4/IMA (first and second panels lanes 1 and 2, respectively) cells using Western blotting. Actin was used as a loading control (third panel).
(C-D). Effects of knockdown of SK-1 and/or S1P2 using siRNAs on imatinib-induced growth inhibition (C) or Bcr-Abl1 (total) and P-Bcr-Abl1 expression (D first and second
panels lanes 2-4) compared with controls (lane 1) in LAMA-4/IMA cells were determined using trypan blue exclusion and Western blotting, respectively. These experiments
were performed in duplicates, and error bars represent SD. *P  .05 was considered significant. In panels B and D, relative expression levels of Bcr-Abl1 or P-Bcr-Abl1
(normalized to actin levels) are shown below each lane.
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In contrast, overexpression of SK-1 in sensitive K562 cells
increased P-Bcr-Abl1 (Y245) of 4-fold compared with controls
(Figure 4E). This effect was concomitant with increased levels of
inactive forms of P-PP2A (Y307) and P-SHP1 (S591) around 3-
and 1.5-fold, respectively, without increasing total PP2A or SHP1
protein expression (Figure 4E left and right panels lanes 2-1, and
4-3, respectively). Overall, these data indicate that activation of
SK-1/S1P signaling regulates Bcr-Abl1 stability and drug resis-
tance via inhibition of PP2A/SHP1 axis, and knockdown of SK-1
mediates down-regulation of Bcr-Abl1 by activation of PP2A.
Role of PP2A in the regulation of Bcr-Abl1 in response to
targeting SK-1/S1P/S1P2 signaling
The involvement of PP2A and SHP1 in the regulation of Bcr-Abl1
by S1P2 signaling was assessed. S1P2 knockdown in K562/IMA-3
cells led to a 60%-70% decrease in inactive forms of PP2A
(P-PP2A) and SHP1 (P-SHP1), respectively (Figure 5A second left
and right panels lanes 2-1, respectively). Accordingly, around 30%
decrease in P-Bcr-Abl1 was observed on S1P2 knockdown (Figure
5A bottom left panel lanes 2-1, respectively). Thus, these data
suggest that knockdown of S1P2 activates PP2A/SHP1 axis,
concomitant with down-regulation of Bcr-Abl1.
To define the role of PP2A in the regulation of Bcr-Abl1, we
over-expressed PP2Ac in K562/IMA-3 cells, and determined its
effects on Bcr-Abl1 expression. Overexpression of the catalytic
domain of PP2A (PP2Ac)-HA, confirmed by Western blotting
(Figure 5B third panel lanes 2-1, respectively), reduced the levels
of P-Bcr–Abl1 and total Bcr-Abl1 compared with vector-
transfected controls (Figure 5B first and second panels lanes 2-1,
respectively). In addition, ectopic PP2Ac-HA expression decreased
the viability of K562/IMA-3 cells in response to imatinib (0.5M;
around 40%; Figure 5C). Importantly, when cells that over-express
PP2Ac were treated with an inhibitor of SK, SKI-II,37 growth
inhibitory effect of imatinib was further enhanced (around 65%),
compared with controls (Figure 5C). Thus, these data indicate that
activation of PP2A signaling reduces Bcr-Abl1 and induces
imatinib-mediated growth inhibition in the absence/presence of
SKI-II in K562/IMA-3 cells.
Then we examined the effect of pharmacologic inhibition of
SK-1 and S1P2 on PP2A activity. As expected, PP2A activity was
lower (around 50%) in resistant compared with parental K562 cells
(Figure 5D). Inhibition of S1P2 using JTE-013,34 alone or in
combination with an SK inhibitor, SKI-II37 increased PP2A activity
approximately 2.5- or 3-fold, respectively in K562/IMA-3 cells
Figure 4. Regulation of Bcr-Abl1 expression levels by SK-1/S1P signaling via the modulation of PP2A. (A) Effects of the down-regulation of SK-1 using siRNA on
Bcr-Abl1 protein in the absence/presence of okadaic acid (OA; 10nM) or SS (10M), inhibitors of PP2A or SHP1, respectively, for 24 hours were determined by Western
blotting, and the Scr-siRNA transfected samples were used as controls. Actin was used as a loading control. (B) Activation of PP2A in response to knockdown of SK-1 using
siRNA in K562/IMA-3 cell extracts was determined ex vivo using the PP2A activity assay kit. (C) Roles of PP2A activation in the regulation of Bcr-Abl1 and P-Bcr-Abl1 in
response to Scr or SK-1 siRNAs were examined in vector controls vs I2PP2A-GFP over-expressing K562/IMA-3 cells using Western blotting (first and second panels lanes 1-2
and 3-4, respectively). Effects of vector-only and I2PP2A overexpression on total and P-PP2A at Y307 (inactive form) in Scr or SK-1 siRNA treated K562/IMA-3 cells were also
determined using Western blotting (third and fourth panels lanes 1-2 and 3-4, respectively). Actin was used as a loading control (fifth panel). (D) Role of I2PP2A overexpression
in the regulation of cell viability in response to SK-1 siRNA was examined using trypan blue exclusion in drug resistant LAMA-4/IMA cells. (E) Effects of SK-1-V5 overexpression
compared with vector-transfections (lanes 2 and 1, respectively) on the total PP2A or SHP1 vs inactive P-PP2A at Y307, or P-SHP1 at S591 (top left and right first and second
panels, respectively) were measured by Western blotting. Effects of overexpression of SK-1 compared with vector transfections on the levels of P-Bcr-Abl1 at Y245 were
determined by Western blotting (bottom left third panel lanes 2 and 1, respectively). Expression of SK-1-V5 was confirmed using the anti-V5 antibody in Western blotting
(bottom right panel), and -actin was used as a loading control (bottom left third panel). These experiments were performed in duplicates, and error bars represent SD.
*P  .05 was considered significant. In panels C and E, relative expression levels of proteins (normalized to actin levels) are shown below each lane.
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compared with controls in the absence/presence of imatinib (Figure
5D). Interestingly, when SKI-II or JTE/013 were combined with
imatinib, PP2A activity was increased of approximately 2- or
3-fold, respectively (Figure 5D). Moreover, since SKI-II can
inhibit both SK-1 and SK-2, we measured its inhibitory activity
against these enzymes selectively using SK-1/ (wt) and SK-1/
MEFs and C17-sphingosine labeling by LC/MS/MS. Treatment
with SKI-II resulted in the inhibition of C17-S1P generation by
SK-1 and/or SK-2 (around 70%) in wt MEFs, and inhibited
SK-1–generated C17-S1P approximately 30% in SK-2/ MEFs
(Figure 5E), confirming the inhibitory effects of SKI-II on SK-1
and SK-2. However, since knockdown of SK-2 did not alter
Bcr-Abl1 expression in K562/IMA-3 cells (see supplemental
Figure 4), effects of SKI-II on drug-induced cell death, and PP2A
activation are most likely because of inhibition of SK-1 in these
cells. Thus, results shown in Figure 5D suggest that inhibition of
SK-1 and/or S1P2 activate PP2A in the absence/presence of
imatinib.
In addition, effects of S1P1 or S1P2 knockdown using siRNAs
on PP2A activity in the absence/presence of S1P were examined in
parental K562 cells (Figure 5F). Down-regulation of S1P2, but not
S1P1, increased PP2A activity approximately 12-fold. Moreover,
exogenous S1P inhibited PP2A activity by approximately 50%, and
it partially prevented increased PP2A activity in response to S1P2
knockdown (Figure 5F), consistent with the protective effects of
S1P on the Bcr-Abl1 down-regulation induced by S1P2 siRNA (see
Figure 2C). Thus, these data suggest that SK-1/S1P/S1P2 signaling
regulates Bcr-Abl1 stability via modulating PP2A activity in K562
cells. These data also suggest that targeting/inhibition of SK-1/
S1P2 decreases the stability of P-Bcr-Abl1 via induction of PP2A
activity, which is prevented by exogenous S1P.
Inhibition of SK-1/S1P2 signaling increases imatinib-induced
cell death in drug resistant CML cells
Because targeting/inhibition of SK-1/S1P2 axis increased PP2A
activity, thereby decreasing Bcr-Abl1 and P-Bcr-Abl1 stability, this
should also enhance imatinib-induced apoptosis and attenuate drug
resistance. Thus, K562, K562/IMA-1, or K562/IMA-3 cells were
treated with increasing concentrations of imatinib in the absence/
presence of SKI-II (20-30M) and/or JTE-013 (10M), and their
effect on PP2A activity, Bcr–Abl1 expression and growth inhibi-
tion, and/or apoptosis was assessed. Cotreatment with SKI-II and
JTE-013 (48 hours) significantly ( 80% induction) increased
imatinib-induced apoptosis in K562 (0.1M), K562/IMA-1 (1M)
and/or K562/IMA-3 cells (0.5M; supplemental Figures 5A-B,
Figure 5. Role of PP2A activation in the regulation of Bcr-Abl1 in response to SK-1/S1P2 targeting. (A) Effects of knockdown of S1P2 in K562/IMA-3 cells using siRNA
compared with Scr-transfected controls (lanes 2 and 1, respectively) on total and P-PP2A and P-SHP1 (at Y307 and S591, respectively), were assessed by Western blotting
(left and right top and middle panels, respectively). Effects of knockdown of S1P2 on the expression of P-Bcr-Abl1 at Y245 were also determined by Western blotting compared
with Scr controls (bottom left panel lanes 2 and 1, respectively). -actin was used as a loading control (bottom right panel). (B) Effects of overexpression of PP2Ac-HA on the
levels of P-Bcr-Abl1 (Y245), or total Bcr-Abl1 (first and second panels) were determined by Western blotting, compared with controls (lanes 2-1, respectively). Expression of
PP2Ac-HA was also confirmed in these experiments (third panel). (C) Inhibition of growth in response to imatinib (0.5M for 48 hours) in the absence/presence of PP2Ac-HA
overexpression and/or SKI-II in K562/IMA-3 cells was examined using trypan blue exclusion. (D) Effects of targeting SK and S1P2 using small molecule inhibitors SKI-II and
JTE-013, respectively, on PP2A activity levels in extracts isolated from K562 and K562/IMA-3 cells in the absence or presence of imatinib compared with untreated controls
were measured as described in “Measurement of PP2A activity.” (E) Inhibitory effects of SKI-II on SK-1 and SK-2 enzyme activities in wt MEFs, versus SK-1 activity on SK-2/
MEFs were measured using C17-Sph labeling followed by measurement of C17-S1P generation in cells by LC/MS/MS. (F) Effects of knockdown of S1P1 or S1P2 using siRNAs
on PP2A activity in the absence/presence of exogenous S1P (1M) in sensitive K562 cell extracts were measured using the PP2A activity assay kit. Scr siRNA was used as a
control. These experiments were performed in duplicates, and error bars represent SD. *P  .05 was considered significant. In panels A and B, relative expression levels of
proteins (normalized to actin levels) are shown below each lane.
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and Figure 6A, respectively). Similar effect was observed on SK-1
knockdown, which enhanced imatinib-induced cell death in resis-
tant K562/IMA-3 cells (Figure 6B).
Mechanistically, the ubiquitination of Bcr-Abl1 was reduced in
K562/IMA-3 compared with K562 cells, and treatment of these
cells with a proteasome inhibitor lactacystin (LACT) increased the
levels of ubiquitinated Bcr-Abl1 (supplemental Figure 6A lanes
1-2 and 3-4, respectively). In fact, ubiquitination of Bcr-Abl1 was
reduced in resistant compared with sensitive K562 cells, trans-
duced with an HA-ubiquitin construct, and LACT treatment
restored the levels of HA-ubiquitinated Bcr-Abl1 in these cells
(supplemental Figure 6B lanes 1-2 and 3-4, respectively). Treat-
ment of drug resistant K562/IMA-1 cells with SKI-II and/or
JTE-013 (alone or in combination) also increased the ubiquitina-
tion of Bcr-Abl1 compared with untreated controls (supplemental
Figure 6C lanes 4-1). Importantly, knockdown of SK-1 decreased
Bcr-Abl1 and P-Bcr-Abl1 around 40% and 65%, respectively, and
proteasome inhibition by LACT almost completely prevented
down regulation of Bcr-Abl1 in response to SK-1 siRNA in
K562/IMA-3 cells (Figure 6C lanes 2 and 4 top and middle panels).
Interestingly, LACT did not have any detectable effect on down-
regulation of P-Bcr-Abl1 (Y245) in response to SK-1 knockdown
(Figure 6C middle panel lanes 2 and 4, respectively), indicating
that proteasomal degradation is regulated down-stream of dephos-
phorylation of Bcr-Abl1. Taken together, these data suggest that
pharmacologic and molecular targeting of SK-1/S1P2 enhance
imatinib-induced apoptosis, and attenuate drug resistance by
induction of PP2A-dependent Bcr-Abl1 dephosphorylation, and
subsequent ubiquitination and proteasomal degradation in drug-
resistant cells.
Targeting of SK-1 and S1P2 signaling in MNCs isolated from
bone marrow of TKI-sensitive and -resistant CML patients
To validate the data obtained in K562 and LAMA4 derivative cell
lines, the proapoptotic effects of targeting SK1/S1P2 signaling
were evaluated in MNCs, isolated from bone marrow of CML-CP
(patient 1) and CML-BC (patients 2 and 3) patients. CML cells
were exposed to increasing concentrations (0.5-1M) of imatinib
in the presence/absence of SKI-II and/or JTE-013. As shown in
supplemental Figure 7A through C, SKI-II and JTE-013, alone or in
combination, significantly enhanced the growth inhibitory effects
of imatinib. The ability of SKI-II and JTE-013 to increase
sensitivity to TKIs was also evaluated in CD34 progenitors
isolated from a CML-BC patient 4, bearing the imatinib-, nilo-
tinib-, and dasatinib-resistant T315I-BCR-ABL1 mutant (Figure
6D). Note that SK-1 and S1P2 mRNA levels were 2.5- and 10-fold
higher, respectively, in MNCs from CML-BC (patient 4) than
healthy individuals (supplemental Figure 7D). Treatment with
SKI-II or JTE-013 to inhibit SK-1/S1P2 signaling in the absence/
Figure 6. Effects of the inhibition of SK-1 and S1P2 on imatinib- or nilotinib-induced apoptosis in K562/IMA-3 and MNCs obtained from a CML patient at BC with the
T315I-Bcr-Abl1 expression. (A) Imatinib-induced apoptosis (at 0.5M for 24 hours) in the absence/presence of SKI-II, JTE-013 or SKI-II/JTE-013 in combination was
measured using the caspase 3 activity assay in K562/IMA-3 cells. (B) Effects of knockdown of SK-1 using siRNA on the inhibition of survival in response to imatinib treatment
(at 0.3, 0.5, and 1.0M at 48 hours) in K562/IMA-3 cells were determined using trypan blue exclusion. (C) Effects of knockdown of SK-1 using siRNA on total and P-Bcr-Abl1
expression in the absence/presence of LACT (5 M) in K562/IMA-3 cells were assessed by Western blotting compared with Scr siRNA treated controls (top and middle panels
lanes 2-4 and 1-3, respectively). Actin levels were used as loading controls (bottom panel). Relative expression levels of Bcr-Abl1 and P-Bcr-Abl1 (normalized to actin levels)
are shown below each lane. (D) Effects of the inhibition of SK-1 and S1P2 using SKI-II and JTE-013, respectively, alone or in combination, on the survival of MNCs isolated from
a CML patient at BC (patient 4), who expressed the T315I-Bcr-Abl1 who did not respond to any treatment in the clinic, were determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-
dimethyltetrazolium bromide; 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assay in the absence/presence of nilotinib (0.5, 1.0, or 3.0M for 48 hours). The
data represent at least 2 independent trials performed in duplicates, and error bars represent SD. *P  .05 was considered significant.
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presence of nilotinib (1 and 3 M)38 enhanced nilotinib-induced
growth inhibition of CD34 T315I CML-BC progenitors com-
pared with controls (Figure 6D). Thus, these data suggest that
targeting SK-1/S1P2 signaling allow, at least in part, nilotinib-
induced apoptosis in CML-BC progenitors expressing the wt-
and/or T315I mutant of Bcr-Abl1.
Inhibition of SK1 and S1PR2 overcomes resistance to imatinib
or nilotinib in 32Dcl3 cells that express Y253H or T315I mutants
of Bcr-Abl1
To examine whether inhibition of SK1/S1PR2 signaling overcomes
imatinib resistance in cells that express mutant forms of Bcr-Abl1,
murine myeloid 32Dcl3 (32D) cells,39 which stably express wt-,
Y253H- or T315I-Bcr-Abl1 were treated with nilotinib (0.05-
0.5M) in the absence/presence of SKI-II and JTE-013 in combina-
tion, and cell survival was examined using 3-(4,5-dimethylthiazol-
2-yl)-2,5-dimethyltetrazolium bromide; 3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyltetrazolium bromide assays. Vector-transfected cells
were used as controls. The 32D/Y253H-, or 32D/T315I-Bcr-Abl1
(supplemental Figures 8B, or Figure 7A, respectively) cells exhib-
ited resistance to nilotinib when compared with 32D/wt-Bcr-Abl1
cells (supplemental Figure 8A), with IC50 values around 0.5 and
	 0.5 compared with around 0.03M, respectively. The 32D/wt-
32D/Y253H-, or 32D/T315I-Bcr-Abl1 cells overexpressed SK-1
and S1P2 around 20, 45, 50, or 25, 73, 220%, respectively,
compared with 32D/vector cells (supplemental Figure 8C). Remark-
ably, treatment with SKI-II and/or JTE-013 enhanced TKI-induced
growth inhibition against 32D/wt-, 32D/Y253H-Bcr-Abl1, and
32D/T315I-Bcr-Abl1 cells (supplemental Figures 8A-B, and Fig-
ure 7A, respectively). These data were also consistent with
decreased P-T315I-Bcr-Abl1 (at Y177) in response to SKI-II
and/or JTE-013 treatment (Figure 7A right panel). Moreover, SK-1
down-regulation using siRNA also enhanced nilotinib-induced
growth inhibition in 32D/T315I-Bcr-Abl1 cells at 0.05, 0.1, and
0.5M by approximately 30%, 45% and 60%, respectively
(Figure 7B).
These results were also confirmed in animal studies, in which
treatment of severe combined immunodeficiency mice bearing
32D/T315I-Bcr-Abl1–derived allografts with nilotinib in combina-
tion with JTE-013 and/or SKI-II significantly (around 50%-70%,
Figure 7. Effects of the inhibition of SK-1 and S1P2 on nilotinib-induced apoptosis in drug resistant 32D cells, expressing the T315I-Bcr-Abl1 in situ and in severe
combined immunodeficiency mice in vivo. (A) 32D/T315I-Bcr-Abl1 cells were treated with increasing concentrations of nilotinib (0.05, 0.1, and 0.5M for 48 hours) in the
absence/presence of SKI-II or JTE-031 (alone or in combination), and then their effects on cell survival were measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-
dimethyltetrazolium bromide; 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assay (left panel). Effects of nilotinib, SKI-II, JTE-013, or SKI-II/JTE-013 treatments
on the levels of P-T315I-Bcr-Abl1, normalized to actin levels, were determined by Western blotting using the antibody that recognizes P-Bcr-Abl1 at Y177 compared with
untreated cells. Relative expression levels of P-Bcr-Abl1 (normalized to actin levels) detected in Western blots are shown (right panel). (B) Role of SK-1 in the regulation of
nilotinib-mediated growth inhibition (at 0.05, 0.1, and 0.5M for 48 hours) was examined using trypan blue exclusion in the absence/presence of Scr or SK-1 siRNAs in
32D/T315I-Bcr-Abl1 cells. The data represent at least 2 independent trials performed in duplicates, and error bars represent SD. (C) Effects of the inhibition of SK-1 and S1P2
using SKI-II and JTE-013 in the absence/presence of nilotinib on the growth of 32D/T315I-Bcr-Abl1–derived tumors (n  8) were determined in severe combined
immunodeficiency/Balb/c mice. Mice containing 32D/wt-Bcr-Abl1– or 32D/T315I-Bcr-Abl1–derived allografts were treated with nilotinib at 10 mg/kg (every 3 days for 18 days),
and untreated mice were used as a control (left panel). Mice containing the 32D/T315I-Bcr-Abl1–derived allografts were treated with 10 mg/kg nilotinib in the absence/presence
of SKI-II and/or JTE-013 at 15, or 0.5 mg/kg,37,34 respectively (right panel). Treatments were performed at days 1, 8, 15, and tumor growth was measured at days 1, 6, 11, 14, and
18 after treatments. Error bars represent SD, and *P  .05 was considered significant. (D) The proposed mechanism by which SK-1/S1P/S1P2 signaling regulates drug
resistance. Regulation of drug resistance by SK-1/S1P involves the modulation of PP2A-dependent and SHP1-mediated degradation of Bcr-Abl1 (wt and mutants) selectively
via S1P2 signaling. In addition, targeting SK-1/S1P2 signaling using pharmacologic (SKI-II and/or JTE-013) or molecular (siRNAs against SK-1 or S1P2) tools induces PP2A
activity, leading to degradation of Bcr-Abl1, and attenuate resistance to TKIs (imatinib or nilotinib).
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P  .05, n  8) reduced tumor growth compared with untreated or
SKI-II/JTE-013-only–treated controls (Figure 7C right panel).
Moreover, expression of the T315I-Bcr-Abl1 resulted in resistance
to nilotinib-induced growth suppression (approximately 50%)
when compared with wt-Bcr-Abl1 expressing 32D-derived allo-
grafts in these mice (Figure 7C left panel). Thus, these data show
that targeting SK1 and S1P2 signaling using pharmacologic or
molecular tools mediate T315I-Bcr-Abl1 dephosphorylation and
instability, and enhance nilotinib-induced growth inhibition in situ
and in vivo.
Discussion
The data presented here revealed that SK-1/S1P-mediated drug
resistance is transduced selectively via S1P2-dependent modula-
tion of PP2A, which attenuates ubiquitination and proteasomal
degradation of Bcr-Abl1, enhancing its stability, and resulting in
subsequent drug resistance (Figure 7D). Moreover, these results
also demonstrate that targeting the SK-1/S1P/S1P2 axis using
SKI-II/JTE/013 or siRNAs presents a novel strategy for overcom-
ing drug resistance (Figure 7D), associated with decreased stability
of Bcr-Abl1 (wt or Y253H and T315I mutants) in CML cells or
progenitors both in situ and in vivo.
Recently, roles of SK-1/S1P signaling in imatinib resistance
were shown in various CML cell lines and MNCs obtained from
CML patients.18,40,41 However, mechanisms of this process,
especially the involvement of S1P2 signaling via activation of
PP2A in the regulation of Bcr-Abl1 (wt and mutants) and drug
resistance were unknown, which is revealed for the first time in
this study. Previously, increased ceramide generation was
implicated in imatinib-induced apoptosis in K562 cells, and
alterations of ceramide/S1P rheostat was reported to mediate
TKI resistance. However, the role of ceramide in the modulation
of Bcr-Abl1 stability, and/or PP2A activation in response to TKI
treatment remains unknown. Since ceramide activates PP2A
partially by prevention of I2PP2A/SET,29 whose overexpression
causes drug resistance in CML,35 it is likely that imatinib-
induced ceramide might mediate PP2A-dependent dephosphory-
lation and inactivation of Bcr-Abl1, leading to its degradation
and increased cell death in CML cells. This view, however,
needs further evaluation.
Inhibition of SK-1 by small molecule inhibitors, such as
SKI-II,37 or neutralizing S1P using a monoclonal antibody42
effectively kill cancer cells, and inhibit tumor growth. Indeed,
SKI-II mediates the proteasome-dependent degradation of SK-1,
leading to the inhibition of S1P generation.43 Consistent with these
data, our results indicate that pharmacologic and/or molecular
inhibition of SK-1 help overcome drug resistance in CML cells via
inducing PP2A-dependent dephosphorylation/inactivation and deg-
radation of Bcr-Abl1.
In this study, we also showed that S1P2 signaling contributes
to drug resistance in CML via attenuation of Bcr-Abl1 dephos-
phorylation/degradation. Overexpression of S1P2 was not suffi-
cient to induce drug resistance, and it required the addition of
S1P in K562 cells, suggesting that SK-1–generated S1P is
necessary for the inhibition of PP2A and regulation of imatinib
resistance upstream of S1P2 signaling. Importantly, in our
studies, targeting S1P2 using JTE-013 or siRNA resulted in the
activation of PP2A and degradation of Bcr-Abl1, which were
partially prevented by exogenous S1P, leading to increased
imatinib-induced apoptosis in drug resistant CML cells. To this
end, the role of S1P2 in CML drug resistance was supported
recently by global siRNA screening studies, in which S1P2
siRNA was found as one of siRNAs to sensitize drug resistant
CML cells.44 In addition to its involvement in drug resistance,
S1P2 also plays an essential role in hypoxia-triggered patho-
logic angiogenesis of the mouse retina, which was suppressed in
S1P2/ knock-out mice.45 Moreover, transforming growth
factor--induced migration and invasion of esophageal cancer
cells was shown to involve SK-1-generated S1P via S1P2
signaling.46 It should be noted, however, that disruption of the
S1P2 gene led to the development of diffuse large B-cell
lymphoma (DLBCL) in approximately half of S1P2/ KO mice
within 1.5 to 2 years of age.47 Thus, long-term targeting of S1P2
might have some unwanted consequences.
The role of PP2A/SHP1-dependent degradation of Bcr-Abl1
has been well documented previously.35 Our data show that
SK-1/S1P/S1P2 signaling inhibits PP2A activity, and thus prevents
PP2A-dependent regulation of Bcr-Abl1 dephosphorylation and
subsequent proteasomal degradation. Interestingly, PP2A was
reported to inhibit SK-1 activity, suggesting an interesting negative
regulatory loop between SK-1/S1P and PP2A activities.48 How-
ever, SK-1/S1P/S1P2–dependent inhibition of PP2A has not been
described previously, and specific signaling cascade involved in
this process remain unknown.
Importantly, targeting SK-1/S1P2 axis was efficacious to over-
come imatinib or nilotinib resistance in 32D/Y253H-Bcr-Abl1 or
32D/T315I-Bcr-Abl1 cells. In addition, MNCs isolated from
CML/BC patients expressing the 3T315I-Bcr-Abl1 were sensitized
to nilotinib in response to SKI-II and/or JTE-013. However,
nilotinib was found to have limited38 or no effect against the
T315I-Bcr-Abl1 mutant previously.49,50 Therefore, there might be
Bcr-Abl1–independent mechanisms of nilotinib-induced cell death
in the absence/presence of SKI-II/JTE-013.
In summary, these data suggest that SK-1/S1P plays important
roles in the regulation of drug resistance in CML selectively via
S1P2-dependent modulation of PP2A, leading to the stability of wt-
and mutant forms of Bcr-Abl1, and drug resistance. Moreover, we
show here that targeting the SK-1/S1P/S1P2 axis presents a novel
therapeutic approach to induce PP2A-dependent dephosphorylation/
inactivation and subsequent degradation of Bcr-Abl1 (wt and the
T315I or Y253H mutants), and overcome TKI resistance both in
situ and in vivo.
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